
Atsena Therapeutics Receives FDA RMAT Designation for Gene Therapy Targeting X-Linked Retinoschisis
Atsena Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational gene therapy, ATSN-201, for the treatment of X-linked retinoschisis (XLRS). …